OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Hepatology is 105. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
JHEP at a glance (October 2024)	2879
Multiplex immunostaining and transcriptomic profiling identify novel immune cell markers for non-alcoholic steatohepatitis and primary sclerosing cholangitis	1719
Non-alcoholic fatty liver disease features a reduced reverse polyunsaturated fatty acid transport (free fatty acids/high-density lipoprotein) from the periphery to the liver	1501
Preclinical pharmacology of low molecular weight GLP-1 receptor agonist XW014	1256
The anti-fibrotic efficacy of Adelmidrol depends in the level of hepatic PPAR gama	1207
The gut (and its microbiota)-liver axis in liver disease associated with alpha-1-antitrypsin deficiency	1094
Viral like particle analysis shows changes with PPIs and may be more sensitive than metagenomics to study PPI modulation of virome in cirrhosis	1060
Gut-liver crosstalk in hepatocellular carcinoma and non-selective beta-blockers: is there a link?	545
Implementation of HCV screening in the 1969–1989 birth-cohort undergoing COVID-19 vaccination: a pivotal study in Italy	395
Outcomes between surgical resection and transarterial chemoembolization in patients with multifocal BCLC-A and Child-Pugh B	360
Liver complications in greek patients with sickle cell disease: a multicenter retrospective analysis from eight thalassemia and sickle cell units across Greece	344
Performance of a p-SWE method implemented on a new ultrasound system for predicting advanced liver fibrosis	338
Multiplexed digital spatial protein profiling reveals potential non-invasive biomarkers to predict advanced fibrosis	294
Altered gut barrier integrity as a mediator of host-microbiome interactions in diabetic patients with advanced Non-alcoholic fatty liver disease	288
Causes of death by fibrosis stage in 959 biopsy-proven NAFLD patients	285
Eliminating viral hepatitis one island at a time-the Hainan experience	284
Prevalence and predictors of HDV viremia in anti-HDV positive patients of the HEllenic multicenter ReAl-life CLInical Study (HERACLIS-HDV)	276
Assessing progress towards achieving regional hepatitis B control goal-nationwide serosurvey among children, Uzbekistan, 2022	265
PNPLA3 rs738409 G allele increases the risk of liver cirrhosis in SERPINA1 MZ heterogygotes	251
The health economic outcomes of trial ACTG5360/MINMON	243
The PNPLA3 genotype is the main driver of weight gain after the hepatitis C cure	241
Oral antibiotic treatment protects mice against the development of diet-induced non-alcoholic fatty liver disease but not against diet-induced intestinal barrier dysfunction	239
The effects of a structured dietetics intervention in patients with non-alcoholic fatty liver disease	235
An explainable artificial intelligence model for prediction of high-risk non-alcoholic steatohepatitis	232
Policy and implementation needs for hepatitis B birth dose in the WHO African region: a survey of national program managers	223

Influence of language barrier and cultural differences in hepatitis B disease knowledge in the chinese community of Barcelona	222
Automation of hepatitis C screening through electronic health record algorithm	220
Hepatitis C seroconversion rates among individuals with repeated testing-Georgia, 2017–2021	219
Booster SARS-CoV-2 vaccination elicits robust antibody response to wild type but not Omicron subvariants BA.4/5 in patients with cirrhosis	218
Liver transplantation for patients with fibrolamellar hepatocellular carcinoma: a comprehensive multicenter analysis to support future decision making	208
A new nuclear-erythroid-2-related factor 2 activator for the treatment of non-alcoholic steatohepatitis: evidence of metabolic and anti-fibroinflammatory effects in human precision cut liver slices	204
Effect of housing temperature on non-alcoholic fatty liver disease development in C57BL/6N mice	203
Diagnostic accuracy of MRE for staging hepatic fibrosis in patients with NAFLD	201
Molecular epidemiology of hepatitis B virus and hepatitis delta virus coinfection in-Sudan	192
Platelet, elastography, age, sex and etiology for hepatocellular carcinoma surveillance in patients with advanced chronic liver disease: Please algorithm	191
Effectiveness and safety of conversion surgery for patients with initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitors: a real-world study	190
Hepatocyte senescence is linked with extrahepatic organ injury, failure of regeneration and mortality in patients with acute indeterminate hepatitis	187
Perturbation of rhythmicity of the circadian clock-oscillator in hepatic stellate cells is associated with liver fibrosis	183
Efficacy and tolerability of atezolizumab and bevacizumab in patients with hepatocellular carcinoma previously treated with systemic therapy: a global, observational study	183
Development of a high precision liver biopsy method to improve the accuracy of fibrosis staging and collagen profiling	178
Beneficial effect of cystic fibrosis transmembrane conductance regulator modulators on adults with cystic fibrosis liver disease	177
The discovery of AMS-I-1274, a high potent and orally active capsid-assembly modulator against hepatitis B virus	175
Outcomes of pregnancy in patients with autoimmune hepatitis in the Netherlands	174
Diagnosis and pathophysiological analysis of sarcopenia using liver MR in chronic liver disease	172
Evaluating pruritus and fatigue in patients with treatment-refractory primary biliary cholangitis	172
Safety and efficacy of the farnesoid X receptor (FXR) agonist cilofexor in a proof-of-concept study in patients with compensated cirrhosis due to primary sclerosing cholangitis (PSC)	168
CyberLiver Animal Recognition Test (CL-ART): a novel remote monitoring tool to assess minimal hepatic encephalopathy	167
Assessment of hepatic fibrosis screening in primary care using the FIB-4 score, followed in second line by an ELF (Enhanced liver Fibrosis) test	166
Sofosbuvir/Velpatasvir/Voxilaprevir for re-treatment in direct-acting antiviral experienced hepatitis C virus patients: a systematic review and meta-analysis	165
Durability of immune response to SARS-CoV-2 vaccination in patients with liver cirrhosis (LC) as compared to healthcare workers (HW)	162
Inclusion of the fatty liver-associated variants in the clinical workup of patients: results of an eight years’ experience in a tertiary referral center with genotyping facility	161
Endoscopic glue injection v/s endoscopic human thrombin injection for bleeding gastric varics -a randomized controlled trial	161
Neutrophil gelatinase-associated lipocalin predicts response to terlipressin and albumin in patients with hepatorenal syndrome	160
Humoral and cellular immune responses to SARS-CoV-2 vaccination across multiple vaccine platforms and liver disease types: an EASL registry multicentre prospective cohort study	157
Bacterial infections in cirrhosis are associated with reduction in gut microbial phage-bacterial interactions	153
miR34a-5p is a target of E2F2 transcription factor in MAFLD-related HCC	150
Temporal trajectory of the model for end-stage liver disease (MELD) score for prediction of mortality among patients with liver cirrhosis	150
TNFR1 inhibition reduces lipogenesis and improves insulin resistance and fibrosis in NAFLD	144
Association between liver cirrhosis and cardiovascular events in a large German cohort-a population based study	144
Toll-like receptor 5 signalling mediates pro-inflammatory and fibrogenic responses in non-alcoholic steatohepatitis (NASH)	144
Circadian sleep-wake rhythms in non-alcoholic fatty liver disease	141
Vitamin D deficiency associates with gut dysbiosis, endotoxemia and the risk of infectious complications in patients with liver cirrhosis	141
Safety, pharmacokinetics, and antiviral activity of the S-antigen Transport Inhibiting Oligonucleotide Polymers (STOPS) drug candidate ALG-010133 in subjects with chronic hepatitis B	141
Reply to: Correspondence on “EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update”	140
THU-192 Liver steatosis assessed by controlled attenuation parameter in patients with primary biliary cholangitis	137
MetALD accounts for a large part of what we call MASLD!	135
SAT-162 Epidemiology and Risk factors for development of AKI-HRS based on the new consensus definition	133
OS-124 Identification and validation of pre-identified morphological baseline features for prediction of fibrosis progression in MAESTRO-NASH	133
THU-069 A composite score of PRO-C6 and platelet count is prognostic for liver-related outcomes in patients with chronic hepatitis C	130
WED-184 Assessment of impact of ascitic fluid polymorphonuclear count on development of spontaneous bacterial peritonitis and survival in patients with liver cirrhosis and ascites	128
FRI-044 Dynamic adaptations of CD8+γδ T cells in acute and chronic hepatitis E virus infection	128
TOP-072-YI Human cirrhotic ascites contains myeloid reprogrammed T-cells capable of enhancing peritoneal immune surveillance	125
WED-164 Cirrhotic patients with acute variceal bleeding and an indication for preemptive-TIPS: real-life results	122
FRI-036 Single nucleotide polymorphisms of the vitamin D receptor and their impact on vitamin D- and Interleukin-6 levels in liver cirrhosis and acute-on-chronic-liver failure	121
SAT-178 Quantitative measurements of prothrombin in patients with cirrhosis and ascites: a validation study	120

SAT-205 Dynopenia predicts mortality in patients with liver cirrhosis and hepatocellular carcinoma	120
THU-133-YI Risk of hypoglycemia in people with cirrhosis without diabetes	120
TOP-508 Derivation and validation of a new donor risk score incorporating graft steatosis and donor diabetes mellitus	120
FRI-062 Trained human bone marrow mesenchymal stem cells enhance immunoregulatory responses and alleviate ConA-induced acute liver failure	119
THU-334 Cholestasis as a predictor of PSC in inflammatory bowel disease: insights from a romanian cohort study	119
FRI-481 Feasibility and effectiveness of liver transplantation following immunotherapy in patients with hepatocellular carcinoma	119
WED-121 Comparison of clinical characteristics, risk factors and prognosis of HCC patients with lean and non-lean MASLD undergoing surgical resection	118
FRI-328 CCL24 blockade alters the proteomic profile of patients with primary sclerosing cholangitis and down-regulates central disease processes	116
SAT-136-YI Identification of prognosis determining risk factors in outpatients with cirrhosis	115
THU-178 Siglec-5 is a functional biomarker that contributes to poor prognosis in patients with liver cirrhosis	115
THU-308-YI Long-term evaluation of controlled attenuation parameter for steatosis monitoring in autoimmune hepatitis	115
WED-145 Morphomolecular proliferative disease and microvascular invasion characterize PET-CT positive hepatocellular carcinoma cases: a single-center pilot study	114
Chimeric Antigen Receptor (CAR) T-cell Therapy: Engineering Immune Cells To Treat Liver Diseases	113
SAT-113 The intratumoral microbiome in HCC and its impact on treatment response	113
SAT-367 UNITED study: results of the up-titration phase of an open label, multicenter, prospective study to characterize the pharmacokinetics and pharmacodynamics of trientine dihydrochloride and to i	112
FRI-260 Identification of hepatitis B virus epitopes presented by human leukocyte antigen A*11:01 as potential targets for immunotherapy	112
WED-262 Prolonged cholestasis following hepatitis A : what lies beneath	112
FRI-258 No evidence for viral escape mutations in immunodominant HCV-specific CD4 T cell epitopes	112
FRI-247 In vitro characterization of elebsiran (VIR-2218), an investigational siRNA therapeutic targeting hepatitis B virus	112
THU-270 HBV genotype association with response to xalnesiran in nucleos (t)ide analogue treated participants with chronic hepatitis B infection in the Piranga phase 2 platform study	110
OS-020 Reviewing the utility of genetic cholestasis testing in adults with cholestatic liver disease	109
LBP-003 DR10624, a first-in-class, FGF21 receptor (FGF21R)/glucagon receptor (GCGR)/GLP-1 receptor (GLP-1R) triple agonist rapidly and significantly reduced liver fat in obese subjects with modest hyp	109
GS-012 Efruxifermin improves fibrosis in participants with compensated cirrhosis due to MASH: results of a 96-week, randomized, doubleblind, placebo-controlled, phase 2b trial (SYMMETRY)	109
OS-044 Liver sinusoidal endothelial cell BRD4 drives inflammatory angiocrine signaling in liver fibrosis	108
FRI-144 Abrogation of hepatic TRb action protects the liver from acute liver injury	108
THU-489 Disruption of receptor-interacting protein kinase 1 post-translational modifications in alcohol-associated liver disease	107
LBP-015 Comparison of endoscopic ultrasound portosystemic gradient with HVPG and direct porto-systemic pressure gradient measurements	106
OS-075 Dual plasma molecular adsorption system therapy in patients with acute-on-chronic liver failure: a non-randomized clustercontrolled study (PADSTONE)	106
FRI-166 Real-world evidence on clinical outcomes and microbiome changes after healthy donor stool transplantation as palliative therapy compared to best supportive care in patients with unstable decom	106
FRI-161 Single-cell RNA sequencing reveals a fundamental role of LCN2+ neutrophils in the innate immune response in drug-induced acute-on-chronic liver failure	105